Synthetic Biologics Inc (NYSE: SYN) announced the peer-reviewed publication of the Phase 1 study investigating intravenous VCN-01 oncolytic adenovirus with or without standard-of-care (SoC) chemotherapy in advanced solid tumors.

• The data, published in the Journal for ImmunoTherapy of Cancer, suggests that treatment with VCN-01 is feasible and has an acceptable safety profile, with encouraging biological and clinical activity.

• In patients with pancreatic adenocarcinoma, overall response rates were 50% (Part 2) and 50% (Part 3).

• VCN-01 viral genomes were detected in tumor tissue in five out of six biopsies (primary pancreatic tumor and liver metastases) on day eight.

• A second peak of virus concentrations in plasma and increased serum hyaluronidase levels suggest replication after IV injection in all patients.

• Higher peaks of hyaluronidase serum levels were associated with maximum tumor shrinkage, and increased levels of immune biomarkers were found in sera after VCN-01 administration.

• Several markers of tumor inflammation were described in tumor biopsies indicating that VCN-01 promotes a change in the tumor immune environment.

• Synthetic Biologics anticipates starting a Phase 2 trial of intravenous VCN-01 combined with SoC chemotherapy as first-line therapy in newly diagnosed metastatic pancreatic adenocarcinoma patients in Q4 of 2022.

• The Company also plans to initiate a Phase 2/3 pivotal trial of intravitreal VCN-01 as an adjunct to chemotherapy or a potential rescue therapy in pediatric retinoblastoma patients in early 2023.

• Price Action: SYN shares are down 2.12% at $0.34 during the market session on the last check Tuesday.

See more from Benzinga

• Why NeoGenomics Stock Is Plunging Today

• Why Novo Nordisk Shares Are Trading Higher Today

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.